Compare CNXC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXC | ADPT |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2020 | 2019 |
| Metric | CNXC | ADPT |
|---|---|---|
| Price | $30.39 | $14.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $54.80 | $17.78 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $9,825,771,000.00 | $276,976,000.00 |
| Revenue This Year | $4.95 | $3.98 |
| Revenue Next Year | $2.50 | $22.72 |
| P/E Ratio | $90.83 | ★ N/A |
| Revenue Growth | 2.15 | ★ 54.77 |
| 52 Week Low | $24.27 | $6.90 |
| 52 Week High | $62.14 | $20.76 |
| Indicator | CNXC | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 52.34 |
| Support Level | $29.35 | $12.22 |
| Resistance Level | $34.64 | $17.72 |
| Average True Range (ATR) | 1.71 | 0.88 |
| MACD | 0.58 | 0.15 |
| Stochastic Oscillator | 91.71 | 67.64 |
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.